Janus Kinase Inhibition to Prevent Ventilator-induced Diaphragm Dysfunction

Recruiting

I'm Interested

Trial ID: NCT03681275

Age - 18 Years-N/A Gender - All Accepting Healthy Volunteers - No

Purpose

We intend, with this study, to prove that blocking the molecular mechanisms whose blockade prevents VIDD in animals, will indeed prevent the development of VIDD in humans as well. We believe that this evidence will serve as the required basis for proceeding with large, ICU-based clinical trial(s) of a drug to prevent VIDD.

Official Title

A Clinical Trial of JAK Inhibition to Prevent Ventilator-induced Diaphragm Dysfunction

Stanford Investigator(s)

Joseph Shrager
Joseph Shrager

Professor of Cardiothoracic Surgery

Eligibility


Inclusion Criteria:

   - Patients undergoing esophagectomy

Exclusion Criteria:

   - Patients with more than mild pulmonary dysfunction

   - Patients with any neuromuscular disease that might compromise diaphragm function

   - Patients with abnormal liver or kidney function

   - Patients taking any immunosuppressant medication (including prednisone) or antifungal
   medications

   - History of tuberculosis

   - Weight loss of >5% of body weight over previous 6 months

   - Pregnancy

View More
View Less

Intervention(s):

drug: Placebo to match tofacitinib

drug: Tofacitinib 10 MG [Xeljanz]

Recruiting

I'm Interested

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Study Team
650-721-6561

©2024 Stanford Medicine